MECHANISMS INVOLVED IN THE DEVELOPMENT OF ADRIAMYCIN RESISTANCE IN HUMAN LEUKEMIC-CELLS

被引:18
作者
KATO, S [1 ]
IDEGUCHI, H [1 ]
MUTA, K [1 ]
NISHIMURA, J [1 ]
NAWATA, H [1 ]
机构
[1] KYUSHU UNIV,FAC MED,DEPT INTERNAL MED 3,3-1-1 MAIDASHI,HIGASHI KU,FUKUOKA 812,JAPAN
关键词
adriamycin; DNA topoisomerase II; glutathione-s-transferase; human leukemic cells; Multidrug resistance; P-glycoprotein;
D O I
10.1016/0145-2126(90)90009-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have developed three adriamycin (ADR)-resistant K562 sublines with different degrees of resistance. These sublines show a decreased accumulation and an increased efflux of ADR in proportion to the degree of resistance. Two membrane proteins (mol. wt 170,000 and 230,000) reactive with monoclonal antibody againstP-glycoprotein were highly expressed in both the K562/ADR200 and the K562/ADR500 subline. Less resistant K562/ADR80 cells contained only small amounts of mol. wt 230,000 protein. Thus, the level ofP-glycoprotein expression was not proportionate to the degree of ADR efflux. Verapamil treatment could not completely reverse ADR resistance. No significant change of glutathione-s-transferase activity nor in the level of DNA topoisomerase II was detected in resistant sublines. In our sublines it seems thatP-glycoprotein is one of the mechanisms for resistance, but additional mechanisms may be involved. © 1990 Pergamon Press plc.
引用
收藏
页码:567 / &
相关论文
共 25 条
[1]  
ARRICK BA, 1984, CANCER RES, V44, P4224
[2]  
BATIST G, 1986, J BIOL CHEM, V261, P5544
[3]   DETECTION OF P-GLYCOPROTEIN IN OVARIAN-CANCER - A MOLECULAR MARKER ASSOCIATED WITH MULTIDRUG RESISTANCE [J].
BELL, DR ;
GERLACH, JH ;
KARTNER, N ;
BUICK, RN ;
LING, V .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) :311-315
[4]  
CAPRANICO G, 1987, CANCER RES, V47, P3752
[5]  
CHOU TH, 1985, P AM ASSOC CANC RES, V26, P855
[6]  
COLE SPC, 1986, CANCER CHEMOTH PHARM, V17, P259
[7]   ACTIVE OUTWARD TRANSPORT OF DAUNOMYCIN IN RESISTANT EHRLICH ASCITES TUMOR-CELLS [J].
DANO, K .
BIOCHIMICA ET BIOPHYSICA ACTA, 1973, 323 (03) :466-483
[8]  
DEFFIE AM, 1988, CANCER RES, V48, P3595
[9]  
HABIG WH, 1974, J BIOL CHEM, V249, P7130
[10]  
INADA M, 1979, CANCER RES, V39, P2200